GlassScriptPhysician profile
Abel Moron
NPI 1033435367
$3,246.73
in general payments reported to CMS, 2019-2025
29 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $621 · 2021: $274 · 2022: $397 · 2023: $262 · 2024: $716 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Education: $19.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.97 |
| Education | $19.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $647.17 | 2022-2025 | Precisetumor, Myrisk |
| Dilon Technologies, INC. | $477.02 | 2024 | Hemoblast Bellows |
| Glaxosmithkline, LLC. | $340.14 | 2019-2025 | Zejula, Jemperli |
| Stryker Corporation | $272.49 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $213.90 | 2019-2021 | |
| Biom'Up France Sas | $184.64 | 2020 | |
| Tesaro, INC. | $164.52 | 2019 | |
| Clovis Oncology, INC. | $130.61 | 2019-2020 | |
| Amgen INC. | $102.47 | 2019-2020 | |
| Boston Scientific Corporation | $95.25 | 2024 | Bodyguardian |
| Merck Sharp & Dohme LLC | $73.43 | 2020-2021 | |
| Heron Therapeutics, INC. | $64.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $51.72 | 2021-2024 | |
| Incyte Corporation | $42.03 | 2022-2025 | Jakafi |
| Kyowa Kirin, INC. | $41.91 | 2020-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $41.06 | 2021-2025 | Tivdak |
| Regeneron Healthcare Solutions, INC. | $37.35 | 2025 | Libtayo |
| Sobi, INC | $31.26 | 2025 | |
| Intuitive Surgical, INC. | $30.50 | 2023 | Da Vinci Surgical System |
| Aveo Pharmaceuticals, INC. | $26.81 | 2025 | |
| Astellas Pharma US INC | $26.42 | 2025 | Prograf |
| Iovance Biotherapeutics, INC. | $26.38 | 2025 | Amtagvi |
| Foundation Medicine, INC. | $24.76 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.43 | 2022 | |
| Abbvie INC. | $17.51 | 2019 | |
| Eisai INC. | $16.37 | 2022 | |
| Coherus Oncology, INC. | $15.42 | 2020 | |
| Genentech USA, INC. | $15.31 | 2019 | |
| Hologic Sales and Service, LLC | $13.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Moron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.